ArticleFrontiers in medicine2026
Heart failure and predictors of outcome in eosinophilic myocarditis: a real-world cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In eosinophilic diseases, myocardial involvement critically impacts prognosis. Given the rarity and heterogeneity of eosinophilic myocarditis (EM), diagnosis and risk-adapted treatment remain challenging, and longitudinal data on cardiac function are scarce. Therefore, this study investigated the course of cardiac function and aimed to identify prognostic biomarkers in a real-world EM cohort across inflammatory disorders. Methods: Clinical, laboratory, and imaging data of all patients with eosinophilic myocarditis treated at Ludwig-Maximilians-University Hospital in Munich between January 2010 and May 2025 were reviewed. Descriptive and inferential statistics were applied to delineate disease courses, treatment regimens, and outcomes. Results: Of 419 patients screened, 51 had EM (51% female patients, mean age 50 ± 14 years). Underlying diseases included eosinophilic granulomatosis with polyangiitis (EGPA, Conclusion: In this real-world cohort, EM severely impacted multiple domains of cardiac function. Treatment patterns were heterogeneous. Baseline NT-proBNP, LVEF, and the Sartorelli score were associated with long-term LVEF and LV remodeling. Baseline evidence of active myocardial inflammation on CMR and/or EMB was associated with subsequent LVEF improvement. Together, these findings support the utility of multimodal biomarkers for risk stratification in EM but require external validation before informing routine care. Prospective multicenter studies using standardized diagnostics and treatment regimens are needed to translate these findings into biomarker-guided management of eosinophilic cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.